Voltage-Gated Potassium Channels in Multiple Sclerosis: Overview and New Implications for Treatment of Central Nervous System Inflammation and Degeneration

By Judge, Susan I. V.; Lee, Jennifer M. et al. | Journal of Rehabilitation Research & Development, January-February 2006 | Go to article overview

Voltage-Gated Potassium Channels in Multiple Sclerosis: Overview and New Implications for Treatment of Central Nervous System Inflammation and Degeneration


Judge, Susan I. V., Lee, Jennifer M., Bever, Christopher T., Jr., Hoffman, Paul M., Journal of Rehabilitation Research & Development


Abstract--Inflammatory tissue damage and the presence of reactive immunocompetent T lymphocytes, macrophages, microglia, and dendritic cells (DCs) are characteristic features in the human chronic inflammatory demyelinating disease, multiple sclerosis (MS). Together, these cells orchestrate the inflammation and immunopathogenesis underlying the MS autoimmune disease processes and all up-regulate the same voltage-gated potassium ([K.sub.v]) channel, [K.sub.v]1.3, when fully activated. Only microglia, which mediate central nervous system (CNS) inflammatory processes (possibly playing a dual role of CNS protection and mediation of neuroinflammation/ neurodegeneration), and DC, which are pivotal to the induction of T cell responses, express the distinct [K.sub.v]1.5 prior to [K.sub.v]1.3 upregulation. Although the precise functional roles of first [K.sub.v]1.5 and then [K.sub.v]1.3 channels are unclear, their differential expression is likely a common mechanism used by both microglia and DC, revealing [K.sub.v]1.5 (in addition to [K.sub.v]1.3) as a potentially important target for the development of new immunomodulatory therapies in MS.

Key words: 3,4 diaminopyridine, 4-aminopyridine, bloodbrain barrier, central nervous system, dendritic cells, experimental allergic encephalomyelitis, multiple sclerosis, murine leukemia virus, voltage-gated potassium channels.

INTRODUCTION

Multiple sclerosis (MS) is a chronic and progressive neurodegenerative disease for which no cure exists. Considered a primary inflammatory disease of central nervous system (CNS) white matter, pathological lesions in MS are characterized by inflammatory demyelination with relative sparing of axons [1], perivascular/parenchymal infiltration of T lymphocytes (T cells) and macrophages [1-3], and proliferation and activation of resident microglia and astrocytes [4], as well as peripheral dendritic cells (DCs) [5]. In addition to inflammation and demyelination (white and gray matter), axonal damage and loss are now recognized as contributing to irreversible deficits in MS [6]. Clinical symptoms include blurred vision, unstable balance, poor coordination, tremors, numbness, and slurred speech, for which the underlying physiological impairment is believed to be conduction block arising from demyelination and inflammation.

Current approaches to treating MS patients include symptomatic treatment of neurological deficits and immunomodulatory therapy to treat neuroinflammation and possibly limit neurodegeneration. Voltage-gated potassium ([K.sub.v]) channels are potential targets for both types of therapies. As symptomatic therapies, only two relatively nonspecific blockers of [K.sub.v] channels, 4-aminopyridine (4-AP) and 3,4 diaminopyridine (3,4-DAP), have been tested clinically for their efficacy in the treatment of patients with MS [7-15]. To date, in vivo immunosuppressive treatments that use nonspecific (4-AP and quinidine) and various highly selective [K.sub.v] channel blockers (margatoxin, correolide, kaliotoxin, ShK, and Sh-Dap22) have been restricted to miniswine [16-17] and rodent experimental allergic encephalomyelitis (EAE) [18-20] animal models for MS.

The first study implicating a [K.sub.v] blocker (quinidine) as a successful therapeutic treatment in an inflammatory demyelinating disease was an animal model performed in rats with experimental allergic neuritis (EAN), an accepted animal model for the human Guillain-Barre syndrome that is the peripheral nervous system (PNS) counterpart of EAE in the CNS. Mix and colleagues demonstrated that injecting EAN rats with quinidine ameliorated symptoms of clinical EAN [21]. These neurological benefits were accompanied with reduced inflammatory infiltrates in target tissue but not improved peripheral nerve conduction, thus foreshadowing the emerging view that [K.sub.v] blockers may primarily exert their neurological benefits in MS through immunomodulatory effects.

TARGETING [K. …

The rest of this article is only available to active members of Questia

Sign up now for a free, 1-day trial and receive full access to:

  • Questia's entire collection
  • Automatic bibliography creation
  • More helpful research tools like notes, citations, and highlights
  • Ad-free environment

Already a member? Log in now.

Notes for this article

Add a new note
If you are trying to select text to create highlights or citations, remember that you must now click or tap on the first word, and then click or tap on the last word.
One moment ...
Default project is now your active project.
Project items

Items saved from this article

This article has been saved
Highlights (0)
Some of your highlights are legacy items.

Highlights saved before July 30, 2012 will not be displayed on their respective source pages.

You can easily re-create the highlights by opening the book page or article, selecting the text, and clicking “Highlight.”

Citations (0)
Some of your citations are legacy items.

Any citation created before July 30, 2012 will labeled as a “Cited page.” New citations will be saved as cited passages, pages or articles.

We also added the ability to view new citations from your projects or the book or article where you created them.

Notes (0)
Bookmarks (0)

You have no saved items from this article

Project items include:
  • Saved book/article
  • Highlights
  • Quotes/citations
  • Notes
  • Bookmarks
Notes
Cite this article

Cited article

Style
Citations are available only to our active members.
Sign up now to cite pages or passages in MLA, APA and Chicago citation styles.

(Einhorn, 1992, p. 25)

(Einhorn 25)

1

1. Lois J. Einhorn, Abraham Lincoln, the Orator: Penetrating the Lincoln Legend (Westport, CT: Greenwood Press, 1992), 25, http://www.questia.com/read/27419298.

Cited article

Voltage-Gated Potassium Channels in Multiple Sclerosis: Overview and New Implications for Treatment of Central Nervous System Inflammation and Degeneration
Settings

Settings

Typeface
Text size Smaller Larger Reset View mode
Search within

Search within this article

Look up

Look up a word

  • Dictionary
  • Thesaurus
Please submit a word or phrase above.
Print this page

Print this page

Why can't I print more than one page at a time?

Full screen

matching results for page

Cited passage

Style
Citations are available only to our active members.
Sign up now to cite pages or passages in MLA, APA and Chicago citation styles.

"Portraying himself as an honest, ordinary person helped Lincoln identify with his audiences." (Einhorn, 1992, p. 25).

"Portraying himself as an honest, ordinary person helped Lincoln identify with his audiences." (Einhorn 25)

"Portraying himself as an honest, ordinary person helped Lincoln identify with his audiences."1

1. Lois J. Einhorn, Abraham Lincoln, the Orator: Penetrating the Lincoln Legend (Westport, CT: Greenwood Press, 1992), 25, http://www.questia.com/read/27419298.

Cited passage

Welcome to the new Questia Reader

The Questia Reader has been updated to provide you with an even better online reading experience.  It is now 100% Responsive, which means you can read our books and articles on any sized device you wish.  All of your favorite tools like notes, highlights, and citations are still here, but the way you select text has been updated to be easier to use, especially on touchscreen devices.  Here's how:

1. Click or tap the first word you want to select.
2. Click or tap the last word you want to select.

OK, got it!

Thanks for trying Questia!

Please continue trying out our research tools, but please note, full functionality is available only to our active members.

Your work will be lost once you leave this Web page.

For full access in an ad-free environment, sign up now for a FREE, 1-day trial.

Already a member? Log in now.